Health Canada Grants Marketing Authorization For TRIKAFTA For People With Cystic Fibrosis Aged 2 Years And Older With Certain Rare Mutations

-Approximately 200 people with certain rare CF mutations are now eligible for TRIKAFTA®-

TORONTO, July 15, 2024 /CNW/ - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive based on clinical and/or in vitro data. TRIKAFTA® was previously approved by Health Canada for use in people with CF aged 2 years and older with at least one F508del mutation and is now approved for 152 additional mutations.

"This expanded approval of TRIKAFTA for patients with a responsive mutation underscores the commitment of our scientists to the development of medicines for all people living with CF," said Michael Siauw, General Manager at Vertex Pharmaceuticals (Canada) Incorporated. "We remain dedicated to the CF community and are excited for the hope this approval brings to newly eligible CF patients and families across the country."